Central Indiana’s radiopharmaceutical industry continues to expand rapidly, earning the state a new title from the U.S. Patent and Trademark Office: Radiopharmaceutical Capital of the World.
Read MoreIndiana has a new name. With its growing field of precision medicine and life sciences, the state has secured the title of Radiopharmaceutical Capital of the World.Â
Read MoreNovartis announced today that it has received approval from the Food and Drug Administration for commercial manufacturing of Pluvicto at its new large-scale, state-of-the-art radioligand therapy manufacturing facility in Indianapolis.
Read More
